Concurrent afatinib and stereotactic body radiotherapy in patient with oligometastatic <i>EGFR</i>-mutated non-small cell lung cancer: a case report and literature review.

ABSTRACT:

Background

Epidermal growth factor receptor (EGFR)-mutated patients treated with target therapy are inevitable to develop resistance to tyrosine kinase inhibitors (TKIs). It has been proved that concurrent stereotactic body radiotherapy (SBRT) and the first-generation TKIs can prolong both progression-free survival (PFS) and overall survival (OS) of EGFR-mutated patients with limited metastases. However, the efficacy and safety of concomitant second-generation TKIs and SBRT is still unknown.

Case description

We for the first time present a stage IVA patient with mutation of both EGFR G719X and L861Q, who after initial response, had developed intracranial progression during afatinib monotherapy. With local treatment for the brain metastasis, she continued

SUBMITTER: Sun L 

PROVIDER: S-EPMC12053448 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature